Treatment Options in Prostate Cancer Once Primary Therapy Fails

Slides:

Advertisements

Similar presentations

Pascal Rischmann European Urology Supplements

Advertisements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Bladder Cancer: Management and Future Directions

Hormone Therapy for Prostate Cancer: Exploring Current Controversies

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Bladder Cancer: A Major Public Health Issue

What is New in Hormone Therapy for Prostate Cancer in 2007?

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

A Novel Treatment of Premature Ejaculation

Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening? Bob Djavan European.

Localised and Locally Advanced Prostate Cancer: Who to Treat and How?

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

Advances in the Therapy of Prostate Cancer–Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways Kurt Miller, Arnulf.

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Richard C. Harkaway European Urology Supplements

RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer Matthew R. Smith European Urology Supplements

Volume 50, Issue 5, Pages (November 2006)

Volume 53, Issue 6, Pages (June 2008)

Risk Factors for the Development of Bone Metastases in Prostate Cancer

Volume 55, Issue 3, Pages (March 2009)

Optimising Hormone Therapy in Advanced Disease

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Current and Future Trends in the Treatment of Renal Cancer

Philip Toozs-Hobson, Pallavi Latthe European Urology Supplements

The Importance of Testosterone Control in Prostate Cancer

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Jacques Irani European Urology Supplements

Optimal Testosterone Control and Eligard®

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Neal Shore European Urology Supplements

Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

The Hallmarks of BPH Progression and Risk Factors

Sergio Bracarda European Urology Supplements

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Jean J.M.C.H. de la Rosette, Vladimir Mouraviev, Thomas J. Polascik

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer P. Mongiat-Artus, P. Teillac

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Richard Berges European Urology Supplements

Axel Heidenreich European Urology Supplements

Improving Flexibility and Quality of Life for Your Patients: A Must?

Bob Djavan European Urology Supplements

Highlighting Unmet Needs: Real Patients, Difficult Choices

The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients Kurt Miller European Urology Supplements Volume.

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

C.G Roehrborn, T McNicholas European Urology Supplements

Beyond Skeletal-Related Events

Manfred Wirth, Peter Iversen, David McLeod, William See

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Epidemiology and Demographics of Prostatitis

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Jan Roigas European Urology Supplements

Axel Heidenreich European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

Michael Marberger European Urology Supplements

Presentation transcript:

Treatment Options in Prostate Cancer Once Primary Therapy Fails Thomas Keane, David Gillatt, Colleen Lawton, Heather Payne, Bertrand Tombal European Urology Supplements Volume 6, Issue 3, Pages 344-353 (March 2007) DOI: 10.1016/j.eursup.2006.12.003 Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 1 Casodex 150mg improves objective progression-free survival in locally advanced prostate cancer, irrespective of primary therapy [17]. Reprinted from McLeod DG, et al. BJU Int 2006;97:247–54, with permission from Blackwell Publishing. European Urology Supplements 2007 6, 344-353DOI: (10.1016/j.eursup.2006.12.003) Copyright © 2006 European Association of Urology Terms and Conditions